Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zocilurtatug pelitecan + atezolizumab + carboplatin
- Development stage
- Phase 1
- Lead developer
- Zai Lab
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
zocilurtatug pelitecan + atezolizumab + carboplatin is an investigational combination regimen being evaluated for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The regimen combines zocilurtatug pelitecan (formerly ZL-1310), a novel antibody-drug conjugate (ADC) targeting Delta-like ligand 3 (DLL3) conjugated to a topoisomerase 1 inhibitor payload, with atezolizumab, an anti-PD-L1 immune checkpoint inhibitor, and carboplatin, a platinum-based chemotherapeutic agent. By combining targeted cytotoxic delivery, immune checkpoint blockade, and systemic chemotherapy, this triplet regimen aims to achieve synergistic antitumor activity and improve outcomes in patients with aggressive neuroendocrine malignancies.
- Other names
- ZL-1310 + atezolizumab + carboplatinzoci + atezolizumab + carboplatinzocilurtatug pelitecan + atezolizumab + carboplatin
02
Targets
DLL3 (Delta-like ligand 3)DNAPDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on zocilurtatug pelitecan + atezolizumab + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zocilurtatug pelitecan + atezolizumab + carboplatin.